show episodes
 
Loading …
show series
 
We have a summary of our thoughts for you on recent news about COVID. We discuss the prospect of FDA authorization of a Moderna booster, 8 lessons for health policy in times of crisis, updates on myocarditis data from Israel and Europe, how our experiences with COVID warn us of the possible end to democracy, how progressivism is dead, why social me…
 
On today's episode we're joined by a number of special guests: Dr. Christopher Booth and Dr. Adam Fundytus of Queen's University in Kingston, Ontario, Dr. Manju Sengar of the Tata Memorial Centre, and Dr. Aaron Goodman of the University of California at San Diego. We talk about their new papers: "Access to cancer medicines deemed essential by oncol…
 
On today's episode, in honor of him and in recognition of his passing, we have an old interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. This interview originally aired as episode 1.49. He wil…
 
Jeremy Loenneke has a Ph.D. in exercise physiology, a Master’s in nutrition and exercise, and is currently the director of the Kevser Ermin Applied Physiology Laboratory at the University of Mississippi, where he focuses his research on skeletal muscle adaptations to exercise in combination with blood flow restriction (BFR). In this episode, Jeremy…
 
Lance Armstrong is a legendary figure in professional cycling having won seven consecutive Tour de France titles but also a controversial figure facing scrutiny for the use of performance enhancing drugs. In this episode, Lance takes us through his meteoric rise to one of the most famous athletes in the world and his equally accelerated fall from g…
 
Steve Rosenberg is the Chief of Surgery at the National Cancer Institute, a position he has held continuously for the past 47 years. Steve is a pioneer in the field of immunotherapies for cancer and a recipient of nearly every major award in science. In this episode, Steve discusses his inspiration for devoting his career to cancer research and des…
 
This week we take a break from #zercovid to give you another episode that's a deep dive into COVID-19. We start with an interview with epidemiologist and infectious disease expert Dr. Daniel Morgan of the University of Maryland School of Medicine; we talk about cognitive errors in medical decision-making and how it relates to COVID-19 health policy…
 
In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss the longevity benefits from greater cardiorespiratory fitness (CRF) and greater muscle mass and strength. Conversely, they dive deep into the literature showing a rapid increase in morbidity and mortality risk as fitness levels decline with age. They also try to tease out the relative c…
 
Today we take a brief break from our #zerocovid mantra to offer you our thoughts on current events. We cover a variety of topics, including: medical doctors in academia, cancelling conferences even for the vaccinated, masking 2-year-olds, equipoise, the CDC Georgia study, myocarditis, booster shots, outdoor masking at Duke, no more zero COVID in Au…
 
Matt Kaeberlein is globally recognized for his research on the biology of aging and is a previous guest on The Drive. In this episode, Matt defines aging, the relationship between aging, chronic inflammation, and the immune system, and talks extensively about the most exciting molecules for extending lifespan. He discusses the current state of the …
 
Lawrence Wright is the author of The Looming Tower: Al-Qaeda and the Road to 9/11 which won the 2007 Pulitzer Prize for general nonfiction and was named one of Time's top 100 books of all time. In this episode, released just before the 20th anniversary of the September 11th attacks, Lawrence and Peter discuss the book and the lasting impact of that…
 
Today we're joined by social epidemiologist, Dr. Maria Glymour of UCSF. We talk about her work in studying public health interventions for dementia and how her experience in academia has led to her conviction in the necessity of rigorous, quantitative technical skills training for epidemiology PhD students. We touch on how to have a good idea, her …
 
We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, includ…
 
In this “Ask Me Anything” (AMA) episode, Peter and Bob answer numerous follow-up questions to recently discussed deep-dive topics such as the use of continuous glucose monitors and getting the most from zone 2 exercise. They also discuss the incredible feats of cyclists in the Tour de France through the lens of the amazing performance physiology re…
 
Today we interview Dr. Bita Fakhri of UCSF on the current research behind treatments for lymphoma. We touch on CAR-T, ABVD, DA-EPOCH-R, and more. We also talk about histiocytic disorders, Dr. Fakhri's career in academia, and learning through teaching.Back us on Patreon! www.patreon.com/plenarysessionCheck out our YouTube channel: www.youtube.com/ch…
 
Today we're compiling all our recent monologues on COVID-19. That's right -- we're taking a break from #zerocovid to give you an episode that's #allcovid! We cover a whole range of news and opinions covering the Delta variant. We give an evidence-based-medicine doctor's take on the question: Are RCTs necessary in the age of COVID19? We also talk ab…
 
Esther Perel is a psychotherapist and New York Times bestselling author who is an expert on modern relationships. In this episode, Esther describes how being a child of parents who narrowly survived the Holocaust shaped and influenced her perspectives and ultimately led to her to a career in therapy. She discusses how the generational differences i…
 
Today we interview Dr. Alan Venook of UCSF, a renowned expert in clinical trial design and gastrointestinal malignancies. We talk about the evolution of the treatment for colorectal cancer over the last few decades, starting with 5FU. We also discuss his time working as an editor for the Journal of Clinical Oncology and we talk about his advice for…
 
Steve Austad is a distinguished professor of biology at the University of Alabama and director of one of the Nathan Shock Centers of Excellence in aging biology. Steve's current research seeks to understand the underlying causes of aging, specifically with a long-term goal of developing medical interventions that slow the age-related decay of human…
 
We have two short thinkpieces for you. The first is on the lessons that can be learned, or have been learned along the way, from publishing 300 peer-reviewed papers in medical/scientific journals. The second is on the recent publication with Jenny Gill out now in the International Journal of Cancer, titled "After COVID-19, telemedicine may be used …
 
Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcom…
 
Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in under…
 
Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal ade…
 
In this “Ask Me Anything” (AMA) episode, Peter and Bob dive deep into cancer screening, including why it’s important, what you need to know about a test, and Peter’s approach with patients. They specifically discuss various screening methods, explain important terms like sensitivity and specificity, and how layering and stacking different tests in …
 
Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal…
 
Katherine Eban is an award-winning investigative journalist who previously appeared on The Drive to discuss the widespread fraud in the generic drug industry. In this episode, she discusses the content of her recent Vanity Fair article, which examined the evidence for the theory that the COVID-19 pandemic resulted from a virus lab escape as opposed…
 
In today's quick episode, we talk about our new paper out now in JAMA Network Open titled "The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval"ODAC Votes: doi.org/10.1001/jamaoncol.2021.3046Back us on Patreon! www.patreon.com/plenarysessionCheck out our YouTube channel: www.youtube.com/channe…
 
Hugh Jackman is an award-winning actor and an overall fascinating and introspective individual. In this episode, Hugh reflects upon his acting career, including how he navigated many tough decisions that led to important professional turning points for him. Peter and Hugh have an intimate discussion related to handling professional criticism, self-…
 
We have a reverse episode for you today! Emma Greenstreet, a second-year medical student at UCSF, interviews our usual host, Dr. Vinay Prasad on why and how he chose hematology/oncology as a specialty, engaging with criticism, mentorship, medical student rotations, choosing a research project, and urging doctors in academia to aim higher. Back us o…
 
We sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions. What Oncologists Can Learn From COVID-19: doi.org/1…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login